英文名稱 |
中文名稱 |
CAS號 |
操作 |
CHMFL-BMX-078 |
化合物CHMFL-BMX-078 |
1808288-51-8 |
詳細(xì)
|
(±)-Zanubrutinib |
(±)-贊魯替尼 |
1633350-06-7 |
詳細(xì)
|
Bosutinib |
伯舒替尼 |
380843-75-4 |
詳細(xì)
|
Nilotinib |
尼羅替尼 |
641571-10-0 |
詳細(xì)
|
Btk inhibitor 2 |
Btk inhibitor 2 |
1558036-85-3 |
詳細(xì)
|
CSF1R-IN-1 |
CSF1R-IN-1 |
2095849-04-8 |
詳細(xì)
|
BMS-935177 |
化合物BMS-935177 |
1231889-53-4 |
詳細(xì)
|
Dasatinib hydrochloride |
達(dá)沙替尼鹽酸鹽 |
854001-07-3 |
詳細(xì)
|
TG 100572 Hydrochloride |
4-氯-3-[5-甲基-3-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-1,2,4-苯并三嗪-7-基]苯酚單鹽酸鹽 |
867331-64-4 |
詳細(xì)
|
AG 1295 |
酪氨酸磷酸化抑制劑AG1295 |
71897-07-9 |
詳細(xì)
|
Dovitinib lactate |
多韋替尼乳酸鹽 |
692737-80-7 |
詳細(xì)
|
Masitinib mesylate |
馬賽替尼 |
1048007-93-7 |
詳細(xì)
|
Motesanib |
莫特塞尼 |
453562-69-1 |
詳細(xì)
|
Sunitinib Malate |
蘋果酸舒尼替尼 |
341031-54-7 |
詳細(xì)
|
Sunitinib |
舒尼替尼 |
557795-19-4 |
詳細(xì)
|
Vandetanib |
凡德他尼 |
443913-73-3 |
詳細(xì)
|
Multi-kinase inhibitor 1 |
化合物MULTI-KINASE INHIBITOR I |
778274-97-8 |
詳細(xì)
|
PD173074 |
PD173074 |
219580-11-7 |
詳細(xì)
|
Toceranib phosphate |
托西尼布磷酸鹽 |
874819-74-6 |
詳細(xì)
|
Tirbanibulin dihydrochloride |
5-[4-[2-(4-嗎啉基)乙氧基]苯基]-N-(苯基甲基)-2-吡啶乙酰胺鹽酸鹽 |
1038395-65-1 |
詳細(xì)
|
Tirbanibulin Mesylate |
1080645-95-9 |
1080645-95-9 |
詳細(xì)
|
Ensartinib hydrochloride |
2137030-98-7 |
2137030-98-7 |
詳細(xì)
|
Tyrosine kinase inhibitor |
DCL000409(XL184) |
1021950-26-4 |
詳細(xì)
|
PF-573228 |
6-[(4-((3-(甲磺酰基)芐基)氨基)-5-三氟甲基嘧啶-2-基)氨基]-3,4-二氫-1H-喹啉-2-酮 |
869288-64-2 |
詳細(xì)
|
SU14813 maleate |
5-[(Z)-(5-氟-1,2-二氫-2-氧代-3H-吲哚-3-亞基)甲基]-N-[(2S)-2-羥基-3-(4-嗎啉基)丙基]-2,4-二甲基-1H-吡咯-3-甲酰胺馬來酸鹽 |
849643-15-8 |
詳細(xì)
|
Ningetinib Tosylate |
對甲苯磺酸寧格替尼 |
1394820-77-9 |
詳細(xì)
|
3-Hydroxy Midostaurin |
CGP52421 |
179237-49-1 |
詳細(xì)
|
INDY |
INDY |
1169755-45-6 |
詳細(xì)
|
KB SRC 4 |
1-[3-[1-([1,1'-Biphenyl]-3-ylMethyl)-1H-1,2,3-triazol-5-yl]phenyl]-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine |
1380088-03-8 |
詳細(xì)
|
SU16f |
化合物 T16947 |
251356-45-3 |
詳細(xì)
|
PF-06465469 |
PF 06465469
Discontinued See A191400 |
1407966-77-1 |
詳細(xì)
|
Vorolanib |
VOROLANIB |
1013920-15-4 |
詳細(xì)
|
Acrizanib |
化合物ACRIZANIB |
1229453-99-9 |
詳細(xì)
|
Vecabrutinib |
維卡布魯替尼 |
1510829-06-7 |
詳細(xì)
|
Lck inhibitor 2 |
3-[[4-[(5-羥基-2-甲基苯基)氨基]-2-嘧啶基]氨基]苯甲酰胺 |
944795-06-6 |
詳細(xì)
|
Osteogenic Growth Peptide (10-14) |
OSTEOGENIC GROWTH PEPTIDE (10-14) |
105250-85-9 |
詳細(xì)
|
N-Deshydroxyethyl Dasatinib |
N-DESHYDROXY ETHYL DASATINIB |
910297-51-7 |
詳細(xì)
|
BRD4 degrader AT1 |
2098836-45-2 |
2098836-45-2 |
詳細(xì)
|
dTRIM24 |
dTRIM24 |
2170695-14-2 |
詳細(xì)
|
BI-3663 |
BI-3663 |
2341740-84-7 |
詳細(xì)
|
BSJ-03-123 |
BSJ-03-123 |
2361493-16-3 |
詳細(xì)
|
PROTAC ERα Degrader-2 |
PROTAC ER Degrader-2 |
1351169-29-3 |
詳細(xì)
|
PROTAC RIPK degrader-2 |
PROTAC RIPK degrader-2 |
1801547-16-9 |
詳細(xì)
|
PROTAC RIPK degrader-6 |
2-[2-[2-[2][4-[(5-苯并噻唑基氨基)-6-[(1,1-二甲基乙基)磺?;鵠-7-喹啉基]氧基]乙氧基]甲氧基]乙基]乙氧基]-N-[2-(2,6-二氧代-3-哌啶基)-2,3-二氫-1-氧代-1H-異吲哚-4-基]-乙酰胺 |
2089205-64-9 |
詳細(xì)
|
SNIPER(BRD)-1 |
SNIPER(BRD)-1 |
2095244-54-3 |
詳細(xì)
|
PAC |
PAC |
2158322-33-7 |
詳細(xì)
|
MS4078 |
MS4078 |
2229036-62-6 |
詳細(xì)
|
MZP-54 |
MZP-54 |
2010159-47-2 |
詳細(xì)
|
MZP-55 |
2010159-48-3 |
2010159-48-3 |
詳細(xì)
|
dBET6 |
1950634-92-0 |
1950634-92-0 |
詳細(xì)
|
PROTAC BET Degrader-10 |
|
1957234-97-7 |
詳細(xì)
|
PROTAC BET degrader-2 |
PROTAC BET DEGRADER-2 |
2093388-33-9 |
詳細(xì)
|
A1874 |
A-1874;A 1874 |
2064292-12-0 |
詳細(xì)
|
VZ185 |
VZ185 |
2306193-61-1 |
詳細(xì)
|
PROTAC FLT-3 degrader 1 |
PROTAC FLT-3 DEGRADER 1 |
2230826-81-8 |
詳細(xì)
|
BETd-246 |
BETD-246 |
2140289-17-2 |
詳細(xì)
|
PROTAC FAK degrader 1 |
PROTAC FAK degrader 1 |
2301916-69-6 |
詳細(xì)
|
MT-802 |
MT-802 |
2231744-29-7 |
詳細(xì)
|
ZXH-3-26 |
ZXH 3-26 |
2243076-67-5 |
詳細(xì)
|
THAL-SNS-032 |
THAL-SNS-032 |
2139287-33-3 |
詳細(xì)
|
BI-4464 |
BI 4464) |
1227948-02-8 |
詳細(xì)
|
NV03 |
化合物 T12271 |
2448341-58-8 |
詳細(xì)
|
CP-10 |
CP-10 |
2366268-80-4 |
詳細(xì)
|
PROTAC Bcl2 degrader-1 |
PROTAC Bcl2 degrader-1 |
2378801-85-3 |
詳細(xì)
|
PROTAC Mcl1 degrader-1 |
PROTAC MCL1 DEGRADER-1 |
2163793-38-0 |
詳細(xì)
|
SIAIS178 |
SIAIS178 |
2376047-73-1 |
詳細(xì)
|
KB02-JQ1 |
6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE-6-ACETAMIDE, N-[2-[2-[2-[[2-[[1-(2-CHLOROACETYL)-1,2,3,4-TETRAHYDRO-6-QUINOLINYL]OXY]ACETYL]AMINO]ETHOXY]ET |
2384184-44-3 |
詳細(xì)
|
PROTAC BRD4 ligand-1 |
PROTAC BRD4 ligand-1 |
2313230-51-0 |
詳細(xì)
|
ARCC-4 |
ARCC-4 |
1973403-00-7 |
詳細(xì)
|
Cereblon modulator 1 |
CC-90009 |
1860875-51-9 |
詳細(xì)
|
CDK9-IN-10 |
4H-1-Benzopyran-4-one, 5,8-dihydroxy-2-phenyl-7-(phenylmethoxy)- |
3542-63-0 |
詳細(xì)
|
Rogaratinib |
羅加替尼 |
1443530-05-9 |
詳細(xì)
|
WEHI-345 analog |
化合物 WEHI-345 ANALOG |
1354825-62-9 |
詳細(xì)
|
Tyrosine kinase-IN-1 |
TYROSINE KINASE-IN-1 |
705946-27-6 |
詳細(xì)
|
PCI-33380 |
1022899-36-0 |
1022899-36-0 |
詳細(xì)
|
CNX-500 |
CNX-500 |
1202758-21-1 |
詳細(xì)
|
N-piperidine Ibrutinib hydrochloride |
3-(4-phenoxyphenyl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
2231747-18-3 |
詳細(xì)
|
Androgen receptor antagonist 1 |
Androgen receptor antagonist 1 |
1338812-36-4 |
詳細(xì)
|
Desmorpholinyl Navitoclax-NH-Me |
化合物DESMORPHOLINYL NAVITOCLAX-NH-ME |
2365172-82-1 |
詳細(xì)
|
SJF620 |
SJF620 |
2376187-16-3 |
詳細(xì)
|
XZ739 |
|
2365172-19-4 |
詳細(xì)
|
PROTAC BRD4 Degrader-5 |
|
2409538-70-9 |
詳細(xì)
|
BSJ-03-204 |
化合物 T30600 |
2349356-09-6 |
詳細(xì)
|
BSJ-04-132 |
BSJ-04-132 |
2349356-39-2 |
詳細(xì)
|
Thalidomide |
沙利度胺 |
50-35-1 |
詳細(xì)
|
ARV-825 |
CS-2252 |
1818885-28-7 |
詳細(xì)
|
Navitoclax-piperazine |
ABT-263-piperazine |
2143096-93-7 |
詳細(xì)
|
Ibrutinib-biotin |
1599432-18-4 |
1599432-18-4 |
詳細(xì)
|
SU4312 |
SU 4312;NSC 86429;SU-4312;NSC-86429 |
5812-07-7 |
詳細(xì)
|
tBID |
1639895-85-4 |
1639895-85-4 |
詳細(xì)
|
Rp-cAMPS triethylammonium salt |
ADENOSINE 3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER, TRIETHYLAMMONIUM SALT |
151837-09-1 |
詳細(xì)
|
Rp-cAMPS sodium salt |
ADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT |
142439-94-9 |
詳細(xì)
|
TAK-659 hydrochloride |
TAK-659 (HYDROCHLORIDE) |
1952251-28-3 |
詳細(xì)
|
Conteltinib |
CONTELTINIB (CT-707) |
1384860-29-0 |
詳細(xì)
|
Lanraplenib succinate |
Lanraplenib (succinate) |
1800047-00-0 |
詳細(xì)
|
Tivozanib |
替沃扎尼 |
475108-18-0 |
詳細(xì)
|
ENMD-2076 |
6-(4-甲基-1-哌嗪基)-N-(5-甲基-1H-吡唑-3-基)-2-[(1E)-2-苯乙烯基]-4-嘧啶胺 |
934353-76-1 |
詳細(xì)
|
Ibrutinib D5 |
伊布替尼布D5 |
1553977-17-5 |
詳細(xì)
|
A-770041 |
A-770041 |
869748-10-7 |
詳細(xì)
|
BPR1K871 |
1-(3-氯苯基)-3-(5-(2-((7-(3-(二甲基氨基)丙氧基)喹唑啉-4-基)氨基)乙基)噻唑-2-基)脲 |
2443767-35-7 |
詳細(xì)
|